Advertisement
Canada markets closed
  • S&P/TSX

    22,269.12
    +197.41 (+0.89%)
     
  • S&P 500

    5,277.51
    +42.03 (+0.80%)
     
  • DOW

    38,686.32
    +574.84 (+1.51%)
     
  • CAD/USD

    0.7339
    +0.0028 (+0.38%)
     
  • CRUDE OIL

    77.18
    -0.73 (-0.94%)
     
  • Bitcoin CAD

    92,585.58
    +110.36 (+0.12%)
     
  • CMC Crypto 200

    1,428.67
    +0.10 (+0.01%)
     
  • GOLD FUTURES

    2,347.70
    -18.80 (-0.79%)
     
  • RUSSELL 2000

    2,070.13
    +13.53 (+0.66%)
     
  • 10-Yr Bond

    4.5140
    -0.0400 (-0.88%)
     
  • NASDAQ

    16,735.02
    -2.06 (-0.01%)
     
  • VOLATILITY

    12.92
    -1.55 (-10.71%)
     
  • FTSE

    8,275.38
    +44.33 (+0.54%)
     
  • NIKKEI 225

    38,487.90
    +433.77 (+1.14%)
     
  • CAD/EUR

    0.6762
    +0.0016 (+0.24%)
     

Investors in MediWound (NASDAQ:MDWD) have seen decent returns of 65% over the past year

Passive investing in index funds can generate returns that roughly match the overall market. But one can do better than that by picking better than average stocks (as part of a diversified portfolio). For example, the MediWound Ltd. (NASDAQ:MDWD) share price is up 65% in the last 1 year, clearly besting the market return of around 26% (not including dividends). So that should have shareholders smiling. Unfortunately the longer term returns are not so good, with the stock falling 33% in the last three years.

With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies.

See our latest analysis for MediWound

MediWound wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. When a company doesn't make profits, we'd generally hope to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

ADVERTISEMENT

In the last year MediWound saw its revenue shrink by 29%. The stock is up 65% in that time, a fine performance given the revenue drop. We can correlate the share price rise with revenue or profit growth, but it seems the market had previously expected weaker results, and sentiment around the stock is improving.

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

earnings-and-revenue-growth
earnings-and-revenue-growth

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

A Different Perspective

It's nice to see that MediWound shareholders have received a total shareholder return of 65% over the last year. That certainly beats the loss of about 7% per year over the last half decade. This makes us a little wary, but the business might have turned around its fortunes. Shareholders might want to examine this detailed historical graph of past earnings, revenue and cash flow.

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.